Prevalence and Consequences of Guideline-Directed Indications for Aortic Valve Replacement in the EARLY TAVR Trial
JACC: Cardiovascular Interventions · 2026-11 · 19 (21) · 2876-2888
DOI: 10.1016/j.jcin.2026.08.016 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026-11. Verfasst von Mahesh V Madhavan und 28 weiteren Autor:innen. Beteiligte Einrichtung: NewYork Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Practice Guidelines as Topic, Aortic Valve, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Edwards Lifesciences Corporation.
Abstract (Originalsprache)
BACKGROUND: The current American College of Cardiology/American Heart Association valvular heart disease guidelines were published before several recent trials that provide greater support for early intervention in patients with asymptomatic severe aortic stenosis (AS). OBJECTIVES: This study sought to investigate the prevalence and clinical impact of American College of Cardiology/American Heart Association Class II recommendations for AVR in the EARLY TAVR trial. METHODS: The EARLY TAVR trial randomized patients with asymptomatic severe AS to transfemoral transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve or clinical surveillance (CS) with conversion to TAVR based on development of ACC/AHA Class I indications. Patients in the intention-to-treat cohort were stratified by presence of a Class II indication for AVR at randomization. The primary endpoint of the present analysis was the composite of all-cause death, stroke, or heart failure hospitalization. Interaction tests were performed to assess whether the treatment effect differed by level of guideline recommendation. Timing of conversion to AVR in the CS group according to the presence/absence of Class II indications was also assessed. RESULTS: Of the 901 patients randomized to TAVR (N = 445) and CS (N = 446), 636 (70.6%) patients had no guideline recommendation, and 265 (29.4%) had at least1 1 Class II recommendation for AVR at the time of randomization. At a median follow-up of 3.8 years, patients with a Class II indication for AVR experienced higher rates of the primary endpoint (Class II: 24.5% vs no recommendation: 14.5%; HR = 1.78; 95% CI: 1.30-2.44; P < 0.001) and were more likely to have acute valve syndrome at the time of conversion. Compared with CS, the relative benefit of early TAVR on the primary endpoint was similar regardless of the presence or absence of a Class II guideline recommendation (HR = 0.62; 95% CI: 0.37-1.02 vs 0.61; 95% CI: 0.40-0.92; Pinteraction = 0.96). CONCLUSIONS: Among patients in the EARLY TAVR trial, Class II indications for AVR were present in almost one-third of patients at baseline. The benefit of early TAVR was consistent regardless of the presence or absence of Class II indications. These findings support the strategy of early TAVR over CS in asymptomatic patients with severe AS, independent of guideline indications. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT03042104; Unique Identifier: NCT03042104.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NewYork Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA.
- NewYork Presbyterian Hospital and Columbia University Irving Medical Center, New York, New York, USA.
- Structural Heart and Valve Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, Canada.
- Cardiovascular Research Foundation, New York, New York, USA; St Francis Hospital and Heart Center, Roslyn, New York, USA.
- UC Health Northen Colorado, Loveland, Colorado, USA.
Förderung
- Edwards Lifesciences Corporation
Zitieren
APA
Madhavan, M. V., Schwartz, A., Lindman, B. R., Pibarot, P., Cohen, D. J., Oldemeyer, J. B., Babaliaros, V., Fearon, W. F., Daniels, D., Chhatriwalla, A., Kavinsky, C. J., Shah, P., Szerlip, M., Dahle, T., Goel, K., O'Neill, W., Makkar, R., Davidson, C., Sheth, T., …, & EARLY TAVR Trial Executive Committee and Study Investigators (2026). Prevalence and Consequences of Guideline-Directed Indications for Aortic Valve Replacement in the EARLY TAVR Trial. JACC: Cardiovascular Interventions, 19(21), 2876-2888. https://doi.org/10.1016/j.jcin.2026.08.016
Vancouver
Madhavan MV, Schwartz A, Lindman BR, Pibarot P, Cohen DJ, Oldemeyer JB, et al. Prevalence and Consequences of Guideline-Directed Indications for Aortic Valve Replacement in the EARLY TAVR Trial. JACC: Cardiovascular Interventions. 2026;19(21):2876-2888. doi:10.1016/j.jcin.2026.08.016
BibTeX
@article{Madhavan2026,
author = {Madhavan, Mahesh V and Schwartz, Allan and Lindman, Brian R and Pibarot, Philippe and Cohen, David J and Oldemeyer, J Bradley and Babaliaros, Vasilis and Fearon, William F and Daniels, David and Chhatriwalla, Adnan and Kavinsky, Clifford J and Shah, Pinak and Szerlip, Molly and Dahle, Thom and Goel, Kashish and O'Neill, William and Makkar, Raj and Davidson, Charles and Sheth, Tej and Sorajja, Paul and DeVries, James and Southard, Jeffrey and Depta, Jeremiah P and Pop, Andrei and Hahn, Rebbecca T and Zhao, Yanglu and Leon, Martin B and Genereux, Philippe and EARLY TAVR Trial Executive Committee and Study Investigators, EARLY TAVR Trial Executive Committee and Study Investigators},
title = {Prevalence and Consequences of Guideline-Directed Indications for Aortic Valve Replacement in the EARLY TAVR Trial},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {21},
pages = {2876--2888},
doi = {10.1016/j.jcin.2026.08.016}
}
EUVIMED